| 图片： | |
|---|---|
| 名称： | |
| 描述： | |
- REGULAR PAP TESTS ARE BEST DEFENSE AGAINST CERVICAL CA..
-
REGULAR PAP TESTS ARE BEST DEFENSE AGAINST CERVICAL CANCER
American Society of Cytopathology to HPV Vaccine Advocates: Emphasize Need for Regular Pap Tests Regardless of Women’s Vaccination Status
Wilmington, Del. - March 19, 2007 - The American Society of Cytopathology today urged clinicians, women’s health advocates and government leaders to remind constituents of the continued need for regular Pap testing regardless of a woman’s vaccination status. In a call to action posted on its Web site, members of the Society expressed concern that this important message was being increasingly omitted from public discussion about the new vaccine. The Society urges HPV vaccine advocates to more aggressively communicate this important message to eliminate the potential for confusion among women.
Cervical cancer is nearly 100 percent curable if detected early. It is estimated that in 2007, about 11,150 cases of invasive cervical cancer will be diagnosed in the United States and 3,670 women will die from the disease. Studies consistently show that the vast majority of women who die from cervical cancer did not receive regular Pap testing. In 2006, the U.S. Food and Drug Administration approved the first vaccine for cervical cancer. The vaccine is intended for girls and young women aged 9-26 for the prevention of cervical cancer and genital warts caused by certain strains of the human papillomavirus (HPV), the virus that causes most cervical cancers. However, the vaccine protects against strains that are responsible for only 70% of cervical cancer, and its long-term safety and efficacy is unknown. Therefore, all women must continue to seek routine gynecological care and regular Pap testing as directed by their doctor.
“While the new HPV vaccine is a very exciting development in women’s health, it does not eliminate the need for regular Pap testing,” said Dr. Mary Sidawy, ASC President “Regular Pap testing is the gold standard for cervical cancer prevention: It’s broadly accessible, inexpensive and backed by nearly 70 years of science. We urge all who are championing the adoption of the HPV vaccine to clearly and aggressively remind women of the need for regular Pap testing to safeguard their health.”
标签：
×参考诊断
-
其实大家都知道液基为什么贵，按理说现在在中国市场上液基产品非常多了，质量良莠不齐，竞争异常激励，价格会因为竞争而降下来，医院有非常大的选择权，有的销售商给妇科医师开一张液基就可以提成回扣30－50元，出报告科室为了经济效益选择质量没有保障的产品，成本极其低廉，可是收费时一点不含糊，这也是普遍现象。其二，传统巴氏宫颈涂片只要临床医师取材和涂片质量高，制片染色佳，细胞医师水平和责任心强，检出率和准确率决不会低于所谓的液基，液基也没有宣传的那么神，关键因素还是在万物之精灵－人，假使患者经济困难干吗非要用液基而放弃传统的巴氏涂片呢，在许多发达国家及中国北京，液基比较盛行的医院，大多数医院都还没有完全停止使用，况且它将继续而长期发挥其价值，所以我不能理解二楼所说因做不起液而放弃宫颈防癌筛查的观点，这一现象的出现是人的问题而不是液基的错。确实是使用液基在一部分医院不一定就能提高阳性检出率，提高诊断的准确率，其原因比较复杂，我们应该辨证去看待它，而不仅仅是一味的说它好还是不好！
-
本帖最后由 于 2007-08-09 23:02:00 编辑
接abin老师的任务，试着翻译了一下，请各位老师批评指教。
常规巴氏涂片检查是预防宫颈癌的最佳措施
美国细胞病理学会（ASC）今天提醒临床医师、妇女健康工作者和政府官员，不管妇女们是否接种宫颈癌疫苗，仍应坚持常规巴氏涂片检查。由于新疫苗问世，公众日益忽视这一重要信息。ASC在其网站发表倡议，对这种状态表示忧虑，并敦促宣传HPV疫苗的人士更加积极地传达这一重要信息，以消除妇女们潜在的认识误区。
早期发现宫颈癌治俞率几乎是100%。据估计，美国2007年发现约11,150 例浸润性宫颈癌，其中有3,670例可能会死于宫颈癌。多项研究结果均一致认为，绝大多数死于宫颈癌的妇女没有接受常规巴氏检测。2006年，美国食品和药品管理局第一次批准宫颈癌疫苗的临床应用。这种疫苗的使用目的，主要是针对人类乳头瘤病毒(HPV)，预防HPV引起的9到26岁女性宫颈癌和生殖器疣。然而，这种疫苗仅能预防70%的宫颈癌的致癌病毒株，并且长期预防作用和有效性还不明确。因此，所有女性必须继续在医生指导下，寻求常规的妇科检查和巴氏涂片检查。
“尽管HPV新疫苗对于女性健康是非常令人振奋的研究成果，但是它并不能取消常规巴氏涂片检查的必要性。”美国细胞学会主席Dr. Mary Sidawy如是说，“常规的巴氏试验是预防宫颈癌的金标准：它能够广泛实施，价格便宜，并且有70年的科学依据。我们会力争所有HPV疫苗的拥护者，要积极、明确地提醒女性采取常规巴氏涂片检查来保护她们的健康。”(abin修改）
- 好好学习
